Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month High – Should You Buy?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $76.76 and last traded at $75.8610, with a volume of 1969376 shares trading hands. The stock had previously closed at $63.88.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Multiple analysts raised price targets (Goldman Sachs to $85, Morgan Stanley to $81, Chardan to $80), suggesting institutional views on longer?term upside. Benzinga Analyst Notes
• Positive Sentiment: Early obesity program data (ARO?INHBE/ARO?ALK7) and interim results showed meaningful weight?loss signals, and news comparing combination results to Lilly’s Zepbound drove investor interest in ARWR’s pipeline potential. Interim Clinical Data
• Positive Sentiment: Unusually high options activity — big uptick in call purchases — indicates speculative bullish positioning that can amplify upside volatility. Options Volume Report
• Neutral Sentiment: Regulatory progress: first?in?class FCS siRNA approval in Canada is a clinical/regulatory milestone, but market reaction has been mixed as investors weigh commercial impact. Canada Approval Coverage
• Negative Sentiment: Arrowhead priced upsized concurrent offerings: $625M 0.00% convertible senior notes due 2032 and 3.1M common shares (plus pre?funded warrants) at $64.50 — a significant dilution event that likely put downward pressure on the share price despite raising cash. BusinessWire Offering Announcement MSN Coverage
• Negative Sentiment: Insider stock sales were reported (multiple officers/directors selling sizable blocks), which can be perceived negatively by investors concerned about timing of the sales relative to the financing. Insider Sale: Patrick O’Brien Insider Sale: James Hamilton Insider Sale: Christopher Anzalone

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ARWR. Chardan Capital upped their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada upped their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Bank of America lifted their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. HC Wainwright boosted their price objective on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Finally, Piper Sandler lifted their price target on shares of Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $71.89.

Arrowhead Pharmaceuticals Trading Up 2.9%

The firm has a market cap of $9.19 billion, a P/E ratio of -840.58 and a beta of 1.21. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $56.34 and its two-hundred day moving average price is $35.95.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the transaction, the director directly owned 33,600 shares of the company’s stock, valued at approximately $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mauro Ferrari sold 7,530 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the transaction, the director directly owned 69,053 shares of the company’s stock, valued at $4,833,710. This represents a 9.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 510,836 shares of company stock valued at $33,603,060. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in Arrowhead Pharmaceuticals by 30.2% during the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 10,496 shares during the period. AQR Capital Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth $514,000. Dynamic Technology Lab Private Ltd boosted its stake in Arrowhead Pharmaceuticals by 40.9% in the first quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 7,827 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after acquiring an additional 447,456 shares during the last quarter. Finally, Empowered Funds LLC grew its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 979 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.